NCT02932891View on ClinicalTrials.gov

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

April 14, 2017

Study Completion Date

December 12, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

DSXS topical

topical treatment

Trial Locations (1)

10532

Taro Pharmaceuticals USA Inc., Hawthorne

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02932891 - An Open Label, Safety Study to Assess the Potential for Adrenal Suppression. | Biotech Hunter | Biotech Hunter